CN105659085B - 预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法 - Google Patents

预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法 Download PDF

Info

Publication number
CN105659085B
CN105659085B CN201480057475.2A CN201480057475A CN105659085B CN 105659085 B CN105659085 B CN 105659085B CN 201480057475 A CN201480057475 A CN 201480057475A CN 105659085 B CN105659085 B CN 105659085B
Authority
CN
China
Prior art keywords
activity profile
subject
gene
group
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480057475.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105659085A (zh
Inventor
郭盛
D·陈
J·张
蔡杰
H·Q·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crown Bioscience Inc Taicang
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Publication of CN105659085A publication Critical patent/CN105659085A/zh
Application granted granted Critical
Publication of CN105659085B publication Critical patent/CN105659085B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201480057475.2A 2013-08-28 2014-08-28 预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法 Active CN105659085B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013082487 2013-08-28
CNPCT/CN2013/082487 2013-08-28
PCT/US2014/053142 WO2015031604A1 (en) 2013-08-28 2014-08-28 Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same

Publications (2)

Publication Number Publication Date
CN105659085A CN105659085A (zh) 2016-06-08
CN105659085B true CN105659085B (zh) 2018-12-07

Family

ID=52587328

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480057475.2A Active CN105659085B (zh) 2013-08-28 2014-08-28 预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法

Country Status (9)

Country Link
US (1) US11136625B2 (https=)
EP (1) EP3039424B1 (https=)
JP (1) JP6612232B2 (https=)
CN (1) CN105659085B (https=)
CY (1) CY1123415T1 (https=)
DK (1) DK3039424T3 (https=)
ES (1) ES2813877T3 (https=)
PT (1) PT3039424T (https=)
WO (1) WO2015031604A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2813877T3 (es) 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
JP6853789B2 (ja) * 2015-12-24 2021-03-31 公益財団法人がん研究会 マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
CN113498341A (zh) * 2019-01-02 2021-10-12 浙江冠科美博生物科技有限公司 使用多靶点激酶抑制剂结合蛋白激酶生物标志物的癌症治疗
CN111521810B (zh) * 2019-02-02 2024-06-21 中国科学院上海药物研究所 癌症患者根据脾酪氨酸激酶进行分层
CN111693707A (zh) * 2020-07-16 2020-09-22 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断血管炎患者中的应用
CN118345086B (zh) * 2024-04-22 2024-10-11 西部(重庆)科学城种质创制大科学中心 柑橘溃疡病抗性Cs7g24050基因及其编码蛋白与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015368A2 (en) * 2007-07-25 2009-01-29 Eisai R & D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer
CN101506351A (zh) * 2005-10-21 2009-08-12 拜尔健康护理有限责任公司 用于癌症预测和预后及监测癌症治疗的方法
CN101541977A (zh) * 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
CN102283836A (zh) * 2011-06-27 2011-12-21 苏州大学附属第一医院 索拉非尼在治疗蛛网膜下腔出血后发生的早期脑损伤的应用
WO2013022995A2 (en) * 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
ATE331514T1 (de) 1999-12-22 2006-07-15 Sugen Inc Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003047579A1 (en) 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
SE0104164L (sv) 2001-12-11 2003-06-12 Ericsson Telefon Ab L M Högspännings-mos-transistor
NO317200B1 (no) 2002-08-09 2004-09-13 Best Practice Deployment As System for trafikkopplaering i et kjoretoy
NZ538982A (en) * 2002-09-27 2008-07-31 Oridis Biomed Forschungs Und E Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
GB0411378D0 (en) 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US20090215835A1 (en) 2005-10-31 2009-08-27 Scott Wilhelm Treatment of cancer with sorafenib
JP2009543797A (ja) 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
US20090062347A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched axitinib
US20090062368A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
NZ583790A (en) 2007-09-10 2012-04-27 Cipla Ltd Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
WO2009054004A2 (en) 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
US20100256392A1 (en) 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220071A2 (en) 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
EP2252607A2 (en) 2008-02-21 2010-11-24 Generics [UK] Limited Novel polymorphs and processes for their preparation
WO2009106825A1 (en) 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
WO2009111061A1 (en) 2008-03-06 2009-09-11 Sicor Inc. Process for the preparation of sorafenib and salts thereof
EP2098521A1 (en) 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
WO2009124037A1 (en) 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
CA2724310A1 (en) 2008-06-23 2009-12-30 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
CA2731605A1 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
US20110301113A1 (en) 2008-09-26 2011-12-08 Concert Pharmaceuticals Inc. Pyridineamine derivatives
WO2010039798A2 (en) 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
US10262103B2 (en) * 2008-11-18 2019-04-16 Raphael LEHRER Individualized cancer treatment
US20100297676A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
AU2010273254A1 (en) 2009-07-16 2012-02-02 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
EP2470212A4 (en) 2009-10-01 2013-12-04 Csl Ltd METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA
WO2011047019A1 (en) * 2009-10-13 2011-04-21 Yale University An objective, quantitative method to predict histological subtype in non-small cell lung cancer
US20120197019A1 (en) 2009-10-23 2012-08-02 Dharmesh Surendra Bhanushali Compositions and processes
UY33164A (es) 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
AR081364A1 (es) 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
WO2011146458A1 (en) 2010-05-18 2011-11-24 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
CA2816559C (en) 2010-11-01 2018-02-13 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-((pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
US9150547B2 (en) 2010-11-29 2015-10-06 Hetero Research Foundation Process for the preparation of pazopanib using novel intermediate
JP6009457B2 (ja) 2010-12-23 2016-10-19 ネクター セラピューティクス ポリマー−デスエチルスニチニブコンジュゲート
WO2012103060A1 (en) 2011-01-27 2012-08-02 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
WO2012116040A1 (en) * 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
WO2013043529A1 (en) 2011-09-19 2013-03-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
CN103826618A (zh) 2011-09-30 2014-05-28 辉瑞大药厂 N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物
US20140322166A1 (en) * 2011-12-12 2014-10-30 Stc. Unm Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
US20140087362A1 (en) * 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
ES2813877T3 (es) 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506351A (zh) * 2005-10-21 2009-08-12 拜尔健康护理有限责任公司 用于癌症预测和预后及监测癌症治疗的方法
CN101541977A (zh) * 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
WO2009015368A2 (en) * 2007-07-25 2009-01-29 Eisai R & D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer
CN102283836A (zh) * 2011-06-27 2011-12-21 苏州大学附属第一医院 索拉非尼在治疗蛛网膜下腔出血后发生的早期脑损伤的应用
WO2013022995A2 (en) * 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods

Also Published As

Publication number Publication date
JP2016528914A (ja) 2016-09-23
CN105659085A (zh) 2016-06-08
DK3039424T3 (da) 2020-08-31
EP3039424B1 (en) 2020-07-29
US11136625B2 (en) 2021-10-05
WO2015031604A1 (en) 2015-03-05
JP6612232B2 (ja) 2019-11-27
PT3039424T (pt) 2020-09-03
US20160208328A1 (en) 2016-07-21
EP3039424A4 (en) 2017-03-29
CY1123415T1 (el) 2021-12-31
EP3039424A1 (en) 2016-07-06
ES2813877T3 (es) 2021-03-25

Similar Documents

Publication Publication Date Title
CN105659085B (zh) 预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法
Matsuura et al. Circulating let‐7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C
US7998674B2 (en) Gene expression profiling for identification of prognostic subclasses in nasopharyngeal carcinomas
JP6704861B2 (ja) 癌処置のための個別化三剤治療を選択するための方法
KR101437718B1 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
US10982286B2 (en) Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
Jour et al. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics
JP2010535473A5 (https=)
US20160053327A1 (en) Compositions and methods for prediction of clinical outcome for all stages and all cell types of non-small cell lung cancer in multiple countries
AU2024203201A1 (en) Multimodal analysis of circulating tumor nucleic acid molecules
CN104508149A (zh) 对jak/stat抑制剂治疗响应的预测
CN108866185A (zh) 用于预测癌症患者中的药物响应性的方法
Zhao et al. Epigenetic alterations of repeated relapses in patient-matched childhood ependymomas
van Engen-van Grunsven et al. Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastastic behavior of uveal melanomas
EP3126521A1 (en) Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer
Byun et al. Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia
CN111617247A (zh) 表皮生长因子受体激酶底物8类蛋白3在增强多靶点激酶抑制剂疗效中的用途
JP2024529939A (ja) 候補薬剤の治療特性を評価するための方法及びモデルシステム、並びに関連するコンピュータ可読媒体及びシステム
WO2023002983A1 (ja) Ｆｇｆｒ阻害薬に対する感受性の判定方法
Bendig et al. IGH:: FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response
US20250305059A1 (en) Predictive biomarkers in colorectal cancer
CN109628598A (zh) 长链非编码rna在肿瘤中的应用
Soares Predictive markers of immunotherapy resistance in lung cancer
JP2025009303A (ja) 白金系抗癌薬の効果予測方法
JP5967699B2 (ja) 遺伝子発現解析による大腸がんの病型分類に基づく抗癌剤応答性及び予後の予測方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant